We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

1st 4 patients in AML treatment combo trial show response

All four adults with hard-to-treat acute myeloid leukemia (AML) who received treatment with a combination of Venclexta (venetoclax) and AB Science‘s experimental therapy AB8939 have responded to treatment, according to an update from AB. The company previously...
Read More

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma

Source: Myeloma : nature.com subject feeds Post Content Read More
Read More

Source: Pharmacy Times articles Post Content Read More
Read More

FDA grants orphan drug status to ARB1002 for pancreatic cancer

A new experimental treatment for pancreatic cancer, ARB1002, has been granted an orphan drug designation by the U.S. Food and Drug Administration (FDA) and is expected to enter early clinical testing later this year. The FDA reserves this status for treatments...
Read More

Is Less “Sufficient” and “Safe” in the MRD Era – Outcomes of Autologous Stem-Cell Transplant as per Melphalan Dose in Patients with Multiple Myeloma

Source: Myeloma : nature.com subject feeds Post Content Read More
Read More

Preclinical study shows RNA therapy halts glioblastoma growth

TTX-MC138, an RNA-based therapy from Transcode Therapeutics that’s in early clinical development, induced tumor cell death and prolonged survival in a mouse model of glioblastoma. That’s according to the study, “Nanotherapy Targeting miR-10b Improves Survival in...
Read More
Latest Data

Latest Publications

The efficacy and safety of CAR-T therapy in relapsed or refractory multiple myeloma patients: a systematic review and meta-analysis

Hematology. 2026 Dec;31(1):2613505. doi: 10.1080/16078454.2026.2613505. Epub 2026 Jan 8. ABSTRACT...
Read More

Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review

Br J Haematol. 2026 Jan 2. doi: 10.1111/bjh.70323. Online ahead of print. ABSTRACT High-dose...
Read More

The efficacy and safety of anti-CD38 monoclonal antibodies in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials

Curr Res Transl Med. 2025 Dec 2;74(1):103559. doi: 10.1016/j.retram.2025.103559. Online ahead of...
Read More

Correction: Chen et al. The Efficacy and Safety of Tandem Transplant Versus Single Stem Cell Transplant for Multiple Myeloma Patients: A Systematic Review and Meta-Analysis. Diagnostics 2024, 14, 1030

Diagnostics (Basel). 2025 Nov 21;15(23):2942. doi: 10.3390/diagnostics15232942. ABSTRACT After...
Read More

Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials

Cancers (Basel). 2025 Nov 21;17(23):3730. doi: 10.3390/cancers17233730. ABSTRACT BACKGROUND:...
Read More

Reduced-versus Standard-dose Melphalan as Single-agent Conditioning Regimen in Auto HSCT for Multiple Myeloma: A Systematic Review and Meta-Analysis

Blood Cell Ther. 2025 Nov 25;8(4):301-310. doi: 10.31547/bct-2025-008. eCollection 2025 Nov 25....
Read More

Email

info@myeloma360.com